Glutamine Cap/Tab
PreclinicalSmall molecule
Glutamine Cap/Tab is one of 6 small molecule programs targeting Lichen Planus. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Lichen Planus
#DrugCompanyPhaseTrials
1Plaquenil
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Cyklokapron
JJ Molner
Phase 2
Glutamine Cap/Tab
HHams Hamed Abdelrahman
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glutamine Cap/Tab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHams Hamed Abdelrahman